
    
      In a non-randomized, prospective, multi-center clinical investigation, approximately 86
      eligible subjects will be enrolled.

      Phase 1: BIOVALVE-I feasibility clinical investigation: Approximately 13 eligible subjects
      will be enrolled.

      Phase 2: BIOVALVE-II pilot clinical investigation: Approximately 73 eligible subjects will be
      enrolled.

      BIOVALVE-I/II subjects follow the same clinical investigation plan (CIP) in all aspects.
    
  